Akari Therapeutics (AKTX) Intangibles (2014 - 2026)

Akari Therapeutics (AKTX) has reported Intangibles for 13 consecutive years, with $30.3 million the latest figure, recorded in Q1 2026.

• Quarterly Intangibles fell 22.66% year-over-year to $30.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.3 million (down 22.66% YoY) and the FY2025 annual result came in at $34.0 million, down 13.22% from the prior year.
• Intangibles fell to $30.3 million in Q1 2026 per AKTX's latest filing, from $34.0 million in the prior quarter.
• Over the last five years, Intangibles for AKTX reached as high as $39.2 million in Q4 2024 and fell as low as $14000.0 in Q4 2023.
• A 5-year average of $21.6 million and a median of $32.2 million in 2025 frame the typical range for Intangibles.
• Annual changes were most pronounced in 2022 — Intangibles slipped 26.24% — and 2024, when it surged 279757.14%.
• Year by year, Intangibles stood at $17000.0 in 2022, then dropped by 17.65% to $14000.0 in 2023, then jumped by 279757.14% to $39.2 million in 2024, then dropped by 13.22% to $34.0 million in 2025, then retreated by 10.88% to $30.3 million in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $30.3 million, $34.0 million, and $34.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.